• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Thursday

    7/27/23 12:17:02 PM ET
    $ABVC
    $ACXP
    $ADTX
    $AREB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

     

    During Thursday, 56 stocks hit new 52-week lows.

    52-Week Low Highlights:

    • Bristol-Myers Squibb (NYSE:BMY) was the biggest company in terms of market cap to set a new 52-week low.
    • American Rebel Holdings (NASDAQ:AREB) was the smallest company in terms of market cap to set a new 52-week low.
    • View (NASDAQ:VIEW)'s stock moved significantly downwards, trading down 5230.71% to reach a new 52-week low.
    • CBL International (NASDAQ:BANL) saw the sharpest rebound, as shares ascended 0.09%, reversing after hiting a new 52-week low.

    Stocks dropping to new 52-week lows on Thursday:

    • Bristol-Myers Squibb (NYSE:BMY) stock broke to a new 52-week low of $60.38 on Thursday. Shares of the company traded down 2.93%.
    • TC Energy (NYSE:TRP) stock hit a new 52-week low of $36.41. The stock was down 1.73% on the session.
    • NovoCure (NASDAQ:NVCR) shares moved down 12.74% on Thursday to hit a new 52-week low of $34.66, drifting down 12.74%.
    • TELUS Intl (NYSE:TIXT) shares hit a yearly low of $9.58. The stock was down 1.34% on the session.
    • MaxLinear (NASDAQ:MXL) stock hit $22.55 on Thursday morning, setting a new 52-week low for a change of down 22.53%.
    • Nexa Res (NYSE:NEXA) shares set a new 52-week low of $4.13. The stock traded down 1.17%.
    • Shyft Group (NASDAQ:SHYF) stock broke to a new 52-week low of $14.14 on Thursday. Shares of the company traded down 29.01%.
    • uniQure (NASDAQ:QURE) shares set a new 52-week low of $9.37. The stock traded up 0.63%.
    • Sharecare (NASDAQ:SHCR) shares fell to $1.15 on Thursday, setting a new 52-week low with a shift of down 9.33%.
    • Luxfer Holdings (NYSE:LXFR) stock hit a yearly low of $12.53. The stock was down 6.72% for the day.
    • Stoke Therapeutics (NASDAQ:STOK) shares were up 0.17% for the day, having made a 52-week low of $5.88.
    • Prelude Therapeutics (NASDAQ:PRLD) shares set a new 52-week low of $4.06. The stock traded down 0.73%.
    • XOMA (NASDAQ:XOMA) stock achieved a new 52-week low on Thursday morning, hitting $15.22 and moving up 1.1%.
    • FibroGen (NASDAQ:FGEN) stock hit a yearly low of $1.82. The stock was down 2.14% for the day.
    • Kezar Life Sciences (NASDAQ:KZR) stock hit $2.19 on Thursday morning, setting a new 52-week low for a change of down 2.88%.
    • Complete Solaria (NASDAQ:CSLR) stock drifted down 7.25% on Thursday morning to hit a new 52-week low of $4.15.
    • NioCorp Developments (NASDAQ:NB) shares set a new 52-week low of $4.52. The stock traded down 0.22%.
    • Beyond Air (NASDAQ:XAIR) stock dropped to a yearly low on Thursday of $3.31. Shares traded down 2.9%.
    • Mersana Therapeutics (NASDAQ:MRSN) stock drifted down 76.38% on Thursday morning to hit a new 52-week low of $0.80.
    • Intensity Therapeutics (NASDAQ:INTS) shares reached a new 52-week low of $5.40 on Thursday morning, moving down 3.89%.
    • MSP Recovery (NASDAQ:LIFW) shares set a new yearly low of $0.20 this morning. The stock was down 7.16% on the session.
    • Celularity (NASDAQ:CELU) shares were up 3.03% for the day, having made a 52-week low of $0.34.
    • Integra Resources (AMEX:ITRG) shares moved down 1.45% on Thursday to hit a new 52-week low of $0.88, drifting down 1.45%.
    • CBL International (NASDAQ:BANL) shares were down 0.09% for the day, having made a 52-week low of $1.59.
    • Nautilus (NYSE:NLS) stock achieved a new 52-week low on Thursday morning, hitting $1.03 and moving down 2.8%.
    • Yellow (NASDAQ:YELL) stock set a new 52-week low of $0.43 on Thursday, moving down 43.14%.
    • Leap Therapeutics (NASDAQ:LPTX) shares moved down 6.2% on Thursday to hit a new 52-week low of $2.38, drifting down 6.2%.
    • View (NASDAQ:VIEW) shares set a new yearly low of $6.08 this morning. The stock was up 5230.71% on the session.
    • ATI Physical Therapy (NYSE:ATIP) stock hit a yearly low of $6.12. The stock was down 7.8% for the day.
    • Purple Biotech (NASDAQ:PPBT) stock hit a yearly low of $1.14. The stock was down 1.69% for the day.
    • Acurx Pharmaceuticals (NASDAQ:ACXP) shares fell to $1.80 on Thursday, setting a new 52-week low with a shift of down 4.71%.
    • Yunji (NASDAQ:YJ) stock hit $1.05 on Thursday morning, setting a new 52-week low for a change of down 1.87%.
    • Better Therapeutics (NASDAQ:BTTX) stock dropped to a yearly low on Thursday of $0.57. Shares traded down 4.29%.
    • BioCardia (NASDAQ:BCDA) shares hit a yearly low of $0.88. The stock was down 6.61% on the session.
    • Capstone Green Energy (NASDAQ:CGRN) stock hit a yearly low of $0.97. The stock was down 11.31% for the day.
    • Addentax Group (NASDAQ:ATXG) stock drifted down 2.12% on Thursday morning to hit a new 52-week low of $3.65.
    • Lytus Technologies Hldgs (NASDAQ:LYT) shares moved down 12.74% on Thursday to hit a new 52-week low of $0.31, drifting down 12.74%.
    • Greenbrook TMS (NASDAQ:GBNH) shares set a new 52-week low of $0.23. The stock traded up 2.74%.
    • ABVC BioPharma (NASDAQ:ABVC) stock set a new 52-week low of $3.26 on Thursday, moving down 37.59%.
    • Golden Minerals (AMEX:AUMN) stock drifted down 1.55% on Thursday morning to hit a new 52-week low of $1.22.
    • Powerbridge Technologies (NASDAQ:PBTS) shares hit a yearly low of $0.29. The stock was down 4.59% on the session.
    • Freight Technologies (NASDAQ:FRGT) stock hit a new 52-week low of $0.63. The stock was down 1.68% on the session.
    • Takung Art (AMEX:TKAT) stock set a new 52-week low of $0.18 on Thursday, moving down 15.97%.
    • Cyclerion Therapeutics (NASDAQ:CYCN) shares set a new 52-week low of $2.88. The stock traded down 2.68%.
    • Ault Alliance (AMEX:AULT) shares set a new 52-week low of $2.95. The stock traded down 10.86%.
    • C3is (NASDAQ:CISS) stock broke to a new 52-week low of $0.62 on Thursday. Shares of the company traded down 3.64%.
    • Avalo Therapeutics (NASDAQ:AVTX) shares set a new 52-week low of $0.21. The stock traded down 7.75%.
    • Aditxt (NASDAQ:ADTX) shares moved up 0.1% on Thursday to hit a new 52-week low of $0.39, drifting up 0.1%.
    • BitNile Metaverse (NASDAQ:BNMV) shares fell to $0.74 on Thursday, setting a new 52-week low with a shift of down 7.99%.
    • Esports Entertainment (NASDAQ:GMBL) stock achieved a new 52-week low on Thursday morning, hitting $0.42 and moving down 7.98%.
    • American Rebel Holdings (NASDAQ:AREB) shares were down 4.93% for the day, having made a 52-week low of $1.56.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $ACXP
    $ADTX
    $AREB

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    uniQure N.V.
    $QURE
    1/28/2026$31.00Equal Weight
    Barclays
    Bristol-Myers Squibb Company
    $BMY
    1/7/2026$65.00Neutral → Buy
    UBS
    Stoke Therapeutics Inc.
    $STOK
    1/5/2026$35.00Buy
    Chardan Capital Markets
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Bristol-Myers Squibb Company
    $BMY
    12/15/2025$61.00Neutral → Buy
    BofA Securities
    Bristol-Myers Squibb Company
    $BMY
    12/12/2025$62.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $ABVC
    $ACXP
    $ADTX
    $AREB
    SEC Filings

    View All

    SEC Form 10-Q filed by NioCorp Developments Ltd.

    10-Q - NIOCORP DEVELOPMENTS LTD (0001512228) (Filer)

    2/6/26 4:36:49 PM ET
    $NB
    Metal Mining
    Basic Materials

    Addentax Group Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ADDENTAX GROUP CORP. (0001650101) (Filer)

    2/6/26 9:15:29 AM ET
    $ATXG
    Professional Services
    Consumer Discretionary

    SEC Form 6-K filed by Nexa Resources S.A.

    6-K - Nexa Resources S.A. (0001713930) (Filer)

    2/6/26 8:38:00 AM ET
    $NEXA
    Metal Mining
    Basic Materials

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on uniQure with a new price target

    Barclays initiated coverage of uniQure with a rating of Equal Weight and set a new price target of $31.00

    1/28/26 7:20:10 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,444 worth of shares (1,100 units at $1.31), increasing direct ownership by 0.41% to 267,966 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    12/17/25 6:32:43 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Addentax Group Corp. Announces Proposed Acquisition of Artificial Intelligence (AI)-empowered and Crypto-enabled Asset Management Platform, with Potential to Generate Approximately HKD 300 Million in Revenue

    SHENZHEN, China, Feb. 6, 2026 /PRNewswire/ -- Addentax Group Corp. (NASDAQ:ATXG) (the "Company", "ATXG", "we", "us" or "our") today announced the proposed strategic acquisition of the offshore wealth management and integrated cross-border service business of Hong Kong-based Riches Group, a provider of global asset allocation and cross-border services. The Company believes that, if completed, the proposed acquisition would support the Company's global expansion strategy by facilitating the integration of Riches Group's offshore business ecosystem, AI-enabled financial solutions, and digital currency/crypto service offerings. Based on preliminary internal estimates and subject to final closing

    2/6/26 9:20:00 AM ET
    $ATXG
    Professional Services
    Consumer Discretionary

    Nexa Achieves 2025 Production, Sales and Costs Guidance, and Provides 2026-2028 Outlook

    Luxembourg, Luxembourg--(Newsfile Corp. - February 6, 2026) - Nexa Resources S.A. (NYSE:NEXA) ("Nexa Resources" or "Nexa" or the "Company") is pleased to announce its operational results for the three-and twelve-month periods ended December 31, 2025. The Company is also providing its production and metal sales guidance for the 2026-2028 period, along with guidance on costs, capital expenditures, and other operating expenses for 2026. The figures presented in this report are preliminary and unaudited. Nexa's financial results for the fourth quarter and full year 2025 are expected to be published on Thursday, February 26, 2026, after trading hours.2025 Summary HighlightsNexa achieved its conso

    2/6/26 9:04:00 AM ET
    $NEXA
    Metal Mining
    Basic Materials

    uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

    ~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~ ~ Six of 11 patients have discontinued enzyme replacement therapy as of data cutoff date ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 06, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated preliminary safety and exploratory efficacy data from 11 patients in its Phase I/IIa trial of AMT-191, an investigational AAV gene

    2/6/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Chemistry Officer Combs Andrew

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    2/5/26 4:14:15 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Scherle Peggy

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    2/5/26 4:12:45 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CLO, CFO, Corp Sec. Lim Bryant David

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    2/5/26 4:11:32 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ADTX
    $AREB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Leadership Updates

    Live Leadership Updates

    View All

    XOMA Royalty Announces CFO Transition

    EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other professional opportunities.   "Tom's leadership, guidance, and resourcefulness have been invaluable as the Company transitioned to and established itself as a royalty aggregator," stated Owen Hughes, XOMA Royalty's Chief Executive Officer.  "On behalf of the Board of Directors and my XOMA Royalty colleagues, I would like to thank Tom for his nearly two decades of service to the Company, his unwavering dedication, and the strong financial foundation h

    1/12/26 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    La Rosa Holdings Corp. Announces Appointment of Nicholas Adler as Chairman of the Board and Chairman of the Compensation Committee

    Celebration, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) ("La Rosa" or the "Company"), a real estate and PropTech company, today announced that the Company's Board of Directors (the "Board") has appointed Mr. Nicholas Adler as a member of the Board, effective December 29, 2025. Upon his appointment, Mr. Adler was also named Chairman of the Board, Chairman of the Compensation Committee, and a member of both the Audit Committee and the Nominating and Corporate Governance Committee. Additionally, on December 29, 2025, Mr. Siamack Alavi notified the Board of his resignation as a director of the Company, effective immediately. Mr. Alavi also stepped down from hi

    12/30/25 8:30:00 AM ET
    $FRGT
    $LRHC
    Professional Services
    Consumer Discretionary
    Real Estate
    Finance

    Novocure Appoints Company President Frank Leonard as Chief Executive Officer

    Novocure (NASDAQ:NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company. "During his more than 15-year career at Novocure, Frank has led many of our global business operations developing deep expertise in delivering our unique, device-based cancer therapy to patients to extend their survivals. Frank has been instrumental in creating Novocure's culture and guiding the organization at critical points, including preparing the company for its first commercial launch and establishing the business functions that continue to

    12/1/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/17/24 5:51:04 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/2/24 4:57:34 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Financials

    Live finance-specific insights

    View All

    Nexa Achieves 2025 Production, Sales and Costs Guidance, and Provides 2026-2028 Outlook

    Luxembourg, Luxembourg--(Newsfile Corp. - February 6, 2026) - Nexa Resources S.A. (NYSE:NEXA) ("Nexa Resources" or "Nexa" or the "Company") is pleased to announce its operational results for the three-and twelve-month periods ended December 31, 2025. The Company is also providing its production and metal sales guidance for the 2026-2028 period, along with guidance on costs, capital expenditures, and other operating expenses for 2026. The figures presented in this report are preliminary and unaudited. Nexa's financial results for the fourth quarter and full year 2025 are expected to be published on Thursday, February 26, 2026, after trading hours.2025 Summary HighlightsNexa achieved its conso

    2/6/26 9:04:00 AM ET
    $NEXA
    Metal Mining
    Basic Materials

    Global Race for Critical Minerals Accelerates as Market Eyes $700B Opportunity by 2030

    NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Critical minerals are becoming one of the most important building blocks of the global economy. Materials like lithium, nickel, cobalt, rare earth elements, and graphite are essential for electric vehicles, renewable energy systems, data centers, smartphones, and defense technologies. As the world shifts toward electrification and clean energy, demand for these minerals is rising quickly, making them a strategic priority for governments and a growing focus for investors while keeping watch on Active Companies that include: North American Niobium (OTCQB:NIOMF) (CSE:NIOB), NioCorp Developments Ltd. (NASDAQ:NB),

    2/5/26 8:45:00 AM ET
    $MP
    $NB
    Metal Mining
    Basic Materials

    Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

    Bristol Myers Squibb (NYSE:BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company's Investor Relations website at http://investor.bms.com to view the detailed fourth quarter and full-year 2025 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here. Company executives will review financial results with the investment community during the call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb:

    2/5/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care